Condition
Masseter Muscle Spasm
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06962007Not ApplicableCompleted
Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal
NCT06408766Completed
Investigating the Effects of Smartphone Use on the Masseter Muscle
NCT02425839Not ApplicableCompletedPrimary
Assessment of Correlation Between Changes of Shear Wave Elastography and Surface Electromyogram of the Masseter
Showing all 3 trials